



Fig. 1. Box plots of exhaled particle number concentration ranging from ≥ 0.52 to $< 1.037 \mu\text{m}$ (A) and from ≥ 1.037 to $20 \mu\text{m}$ (B) without any devices and with nasal cannula device and HFNC device. HFNC = high-flow nasal cannula.

Acknowledgements

The authors are grateful to Mr. Ryuta Okamoto, Mr. Taro Furukawa, and Mr. Kozo Takahashi, who are members of Shin Nippon Air Technologies, and Mr. Susumu Matsumoto, who is a member of Tokyo Dylec Corp, for technical assistance. Also, the authors are grateful to Dr. Tomohiro Handa, Dr. Hiroshi Shima, Dr. Satoru Terada, and Dr. Yusuke Shiraishi for performing the experimental trial with an aerosol particle sizer spectrometer.

Appendix A. Supplementary Data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.arbres.2021.01.011](https://doi.org/10.1016/j.arbres.2021.01.011).

Bibliografía

- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323:1239–42.
- Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. *Lancet Respir Med*. 2020;8:506–17.

- Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Med*. 2020;46:854–87.
- World Health Organization. Clinical management of COVID-19. WHO. 2020;12 <http://www.who.int/publications/i/item/clinical-management-of-covid-19>
- Li J, Ehrmann S. High flow aerosol dispersing- versus aerosol generating procedures. *Am J Respir Crit Care Med*. 2020;202:1069–71.
- Gaeckle NT, Lee J, Park Y, Kreykes G, Evans MD, Hogan CJ Jr. Aerosol generation from the respiratory tract with various modes of oxygen delivery. *Am J Respir Crit Care Med*. 2020;202:1115–24.
- Hamada S, Tanabe N, Inoue H, Hirai T. Wearing of medical mask over the high-flow nasal cannula for safer oxygen therapy in the COVID-19 era. *Pulmonology*. 2020, <http://dx.doi.org/10.1016/j.pulmoe.2020.10.009>.

Satoshi Hamada^a, Naoya Tanabe^{b,*}, Hideki Inoue^c, Toyohiro Hirai^b

^a Department of Advanced Medicine for Respiratory Failure, Graduate School of Medicine, Kyoto University, Kyoto, Japan

^b Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

^c Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan

* Corresponding author.

E-mail address: ntana@kuhp.kyoto-u.ac.jp (N. Tanabe)..

<https://doi.org/10.1016/j.arbres.2021.01.011>

0300-2896/ © 2021 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Diffuse Alveolar Hemorrhage: A Case of Overlap Syndrome of ANCA-Associated Vasculitis in Diffuse Systemic Sclerosis



Hemorragia alveolar difusa: un caso de síndrome de superposición de vasculitis asociada a ANCA y esclerosis sistémica difusa

Dear Editor,

Systemic sclerosis (SSc) is an autoimmune disorder associated with chronic inflammation and vasculopathy that may progress to visceral fibrosis of multiple organs, most commonly the kid-

neys, lungs and heart.¹ Pulmonary manifestations of SSc include pulmonary hypertension (PH) and interstitial lung disease.^{2,3} It is characterized by autoantibody production, such as anti-centromere or anti-Scl70 antibodies, which are of prognostic and clinical relevance.⁴

Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAVs) such as granulomatous polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis are autoimmune disorders characterized by small vessels' inflammation which is directly associated with ANCA production.⁴ Diffuse alveolar hemorrhage (DAH) and rapidly progressive glomerulonephritis are clinical manifestations of those AAVs, which can be life-threatening.³

The presence of ANCA in SSc is uncommon and its clinical significance is controversial, because in spite of its presence, only a minority of patients will develop AAVs.^{1,4} These overlap syndromes are rare and associated with high mortality, so a prompt and strict follow-up is extremely important. Corticosteroids induce a good response, but sometimes cyclophosphamide and plasmapheresis are needed.

The authors present the case of a sixty-two-year-old man, previous smoker of twenty packs/year, retired from automobile painter and construction. He had been diagnosed with ischemic cerebellar stroke, atrial flutter and SSc with diffuse cutaneous, polyarticular and interstitial lung involvement. Serologically characterized by anti-Scl70 antibody positivity. Previously medicated with methotrexate and azathioprine, both suspended because of lack of effectiveness and side effects, and cyclophosphamide in 2014 with good response. Before the present hospitalization he was on mycophenolate mofetil. Following the suspicion of PH in 2017 a right heart catheterization (RHC) was performed, revealing a mean pulmonary artery pressure (mPAP) of 22 mmHg. The patient remained on clinical and echocardiographic monitoring at the pulmonary hypertension clinic.

In January 2019, the patient referred gradual worsening of dyspnea, orthopnea and leg edemas, presenting with tachypnea, diminished pulmonary sounds and crackles. Vital signs were normal apart from peripheral desaturation of 84% at room air. The patient was admitted to our intermediate care unit. Arterial blood gases presented with hypoxemia and hypocapnia, blood test showed no signs of infection, GFR was 85 mL/min and NT-proBNP 2591 pg/mL. Initial X-ray revealed diffuse alterations suggesting fibrosis and right pleural effusion. The thoracic angio-computerized tomography (CT) maintained a stable non-specific interstitial pneumonia pattern, with no thromboembolic pulmonary disease, thus documenting no deterioration when compared with previous imaging; lung function tests were normal, as previously documented, except for the *Diffusing Capacity for Carbon Monoxide* (DLCO) of 21%; echocardiogram documented a pulmonary artery systolic pressure (PSAP) of 65 mmHg, good systolic function of left ventricle, with an ejection fraction of 68%, and diminished systolic function of the right ventricle because of hypokinetics of the free wall. Re-evaluation by RHC showed pre-capillary PH with a mPAP of 31 mmHg, capillary wedge pulmonary pressure (CWPP) of 9 mmHg, cardiac index (CI) of 1.3 L/min/m³ and a pulmonary vascular resistance (PVR) of 9.1 Wood units (Wu). Right heart failure in the context of newly diagnosed PH was assumed and high dose diuretics were initiated. Etiological classification pointed toward group 1 PH⁶ despite the pulmonary interstitial involvement, because FVC was >70%⁷ and DLCO was disproportionately low with a FVC/DLCO ratio of 4.0 (>2.55).⁸ Nevertheless, interstitial involvement was extensive on imaging tests and group 3⁶ was also considered possible. Sildenafil was initiated at a dose of 75 mg/day. Despite initial improvement, on the eleventh day of admission the patient had moderate hemoptysis with worsening respiratory failure that needed high flow nasal cannula oxygen with a FiO₂ of 100%. Hemoglobin level decreased 1.1 g and X-ray presented with diffuse infiltrates. Angio-CT revealed ground glass bilateral opacities predominant on the upper lobes, compatible with alveolar hemorrhage, with no signs of arterial thrombi. On blood analysis there was elevated C-reactive protein and neutrophilia, without leukocytosis. Renal function remained normal. Later on, the lupic anticoagulant, anticardiolipin antibody as well as anti-beta2glycoprotein1, anti-CPP, anti-GBM and ANA antibodies results were negative, while antibodies anti-Scl70 and anti-proteinase, PR3, (92 IU/mL) were positive. Bronchoscopy for bronchoalveolar lavage was not possible because of the severity of the respiratory failure. Large spectrum antibiotics were initiated. Methylprednisolone 1 g/day was also initiated, followed by prednisolone with slight improvement. There

were many risk factors for DAH, such as the ongoing long-term hypocoagulating therapy, which was immediately stopped without any improvement; vasculitic phenomena in the context of the SSc itself^{9,11}; the aggravated PH¹¹ and even the recent introduction of sildenafil.¹⁰ As many of those diagnosis would be by exclusion, the finding of PR3 positivity led to the suspicion of an overlap with AAV. The case was discussed at the multidisciplinary meeting and it was decided to initiate cyclophosphamide, leading to a gradual but clinically relevant improvement. The patient was discharged with long-term oxygen therapy with 1 L/min at rest and 6 L/min on exertion. Therapy with prednisone 20 mg/day, sildenafil 75 mg/day and monthly cyclophosphamide was maintained.

Until 2019 the reported prevalence of ANCA in SSc was between 0 and 12%. Previous studies reported predominance of anti-myeloperoxidase (MPO)² antibody, which is contradicted on the cohort from 2019 by Moxey et al., in which the prevalence of PR3 antibody is higher (15.5% against 11.2%).⁴ Although the real number of patients manifesting AAVs as an overlap syndrome with SSc is unknown, the reported cases is diminished (0.23% of the entire cohort by Moxey et al., and only 2.6% of ANCA positive patients), and the reason why some ANCA positive patients manifest vasculitic symptoms and others do not, is not clear. Also, renal failure is frequently present,¹ which was not the case in our patient. It is recommended to start therapy with corticosteroids. In more severe cases, other immunosuppressants might be indicated. Cyclophosphamide is the first choice for DAH due to AAV and, in our patient, it had been previously used in the course of his disease with favorable outcome. Although the diagnosis of DAH associated to AAV was not possible to confirm, the good response to the treatment favors it. Other immunosuppressants, such as mycophenolate mofetil and rituximab, can also be used. These patients need a tight surveillance because when rapidly found and treated, rapid progression can be avoided and mortality reduced.⁵

Conflict of interest

None.

Bibliografía

1. Arad U, Balbir-Gurman A, Doenya-Barak K, Amit-Vazina M, Caspi D, Elkayam O. *Anti-Neutrophil associated vasculitis in systemic sclerosis*. Elsevier 2011. doi:10.1016/j.semarthrit.2010.11.001.
2. Hashimoto H. Review article microscopic polyangiitis in systemic sclerosis. *Int J Rheumatol*. 2010. <http://dx.doi.org/10.1155/2010/148528>, article ID 148528.
3. Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. *Eur Respir Rev*. 2017;26:170056. <http://dx.doi.org/10.1183/16000617.0056-2017>.
4. Moxey J, Molla-Huq S, Proudman S, Sahhar J, Ngian GS, Walker J, et al. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. *Arthritis Res Therapy*. 2019. <http://dx.doi.org/10.1186/s13075-019-1839-5>.
5. Chaer RA, Massad MG, Evans A, Olopade C, Varga J. *Systemic sclerosis complicated by diffuse alveolar hemorrhage*. *Med Sci Monit*. 2001;7:1013–5.
6. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS); Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPCC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2016;37:67–119. <http://dx.doi.org/10.1093/eurheartj/ehv317>.
7. Galie N, McLaughlin VV, Rubin LJ, Simonneau G. *Pulmonary hypertension in chronic lung disease and hypoxia*. Number 10 in the series "Proceedings of the 6th World Symposium on Pulmonary Hypertension". *Eur Respir J*. 2019;53:1802148. <http://dx.doi.org/10.1183/13993003.02148-2018>.
8. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. *Ann Rheumat Dis*. 2014;73:1340–9.
9. Saab FH, Bajaj T, Bains K, Garcia-Pacheco R. Recurrent episodes of diffuse alveolar hemorrhage in systemic sclerosis 30 days apart. *J Investig Med High Impact Case Rep*. 2019;7. <http://dx.doi.org/10.1177/2324709619846594>, 2324709619846594. Published online 2019 May 3.
10. Philippe Camus MD. Dijon, France. <https://www.pneumotox.com/drug/view/423/sildenafil> [updated 20.01.12].

11. Mandal A, Sahi PK. Pulmonary hemorrhage in children. *Pulm Crit Care Med.* 2016;1. <http://dx.doi.org/10.15761/PCCM.1000121>.

Joana Nascimento^{a,*}, Ana Dias^a, Catarina Resende^b, Ana Mineiro^a, Paula Esteves^a

^a Pulmonology Department in Centro Hospitalar Universitário Lisboa Norte, EPE, Av. Prof. Egas Moniz, n/s, 1649/035 Lisboa, Portugal

^b Rheumatology Department in Centro Hospitalar Universitário Lisboa Norte, EPE, Av. Prof. Egas Moniz, n/s, 1649/035 Lisboa, Portugal

* Corresponding author.
E-mail address: joananascimento60532@gmail.com (J. Nascimento).

<https://doi.org/10.1016/j.arbres.2021.01.013>
0300-2896/ © 2021 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Escalando y desescalando el tratamiento en la enfermedad pulmonar obstructiva crónica. ¿El inhalador importa?



Escalation and De-Escalation of Therapy in Chronic Obstructive Pulmonary Disease. Is the Inhaler Important?

Estimado Director:

La terapia inhalada constituye el pilar fundamental del tratamiento farmacológico de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC)¹. La Guía Española de la EPOC (GesEPOC)², recomienda un tratamiento farmacológico individualizado según las características, nivel de síntomas y riesgo de exacerbaciones del paciente. La estrategia global para el manejo de la EPOC (GOLD)³ apuesta también por un enfoque personalizado y propone, desde su actualización de 2019, la utilización de

algoritmos diferenciados para la elección del tratamiento inicial y de mantenimiento⁴. Estas novedosas propuestas plantean llevar a cabo una evaluación y un ajuste dinámico del tratamiento a lo largo del seguimiento, a través de estrategias de intensificación o reducción (escalado/desescalado), especialmente en aquellos pacientes en los que, pese a exhibir una correcta técnica inhalatoria y cumplimiento del tratamiento pautado, no se haya logrado un adecuado control de la enfermedad.

Si bien, dichas estrategias terapéuticas tienen como objetivo principal mejorar la adecuación del tratamiento farmacológico a lo largo del curso de la enfermedad, pueden conllevar ciertos cambios a tener en cuenta, no solo en los fármacos administrados, sino también en los dispositivos de inhalación que los vehiculizan. Según el documento de consenso sobre terapia inhalada elaborado por la *European Respiratory Society* y la *International Society for Aerosols in Medicine*, cuando un paciente está familiarizado con un dispositivo y realiza correctamente la técnica inhalatoria, este no debe cam-

Inhalador	LABA	LAMA	ICS	LABA/LAMA	LABA/ICS	LABA/LAMA/ICS
En solución	Cartucho	✗		✗		
	Respimat		✗	✗		✗
En polvo multidosis	Accuhaler	✗		✗		✗
	Ellipta	✗		✗		
	Turbuhaler		✗		✗	
	Genuair	✗		✗		✗
	Spiromax	✗	✗	✗		✗
	Easyhaler	✗	✗			✗
En polvo monodosis	Breezhaler				✗	✗
	Handihaler	✗		✗	✗	✗
	Zonda	✗		✗	✗	✗

Figura 1. Principales sistemas de inhalación y fármacos disponibles para el tratamiento de la EPOC. ICS: corticoides inhalados; LABA: β2-adrenérgicos de acción larga; LAMA: antimuscarínicos de acción larga.